Selatogrel_product_DataBase

Bioactivity	Selatogrel is a reversible and selective P2Y12 receptor antagonist which inhibits platelet aggregation with an IC50 of 8 nM. Selatogrel exhibits antithrombotic efficacy[1].
In Vivo	Selatogrel (0-0.1 mg/kg，静脉注射，单剂量) 剂量依赖性地阻断 wistar 大鼠体内由 FeCl3 引起的血栓形成并减少手术中的失血量sup>[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model:
CAS	1159500-34-1
Formula	C28H39N6O8P
Molar Mass	618.62
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Caroff E, et al., 4-((R)-2-{[6-((S)-3-Methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}-3-phosphonopropionyl)piperazine-1-carboxylic Acid Butyl Ester (ACT-246475) and Its Prodrug (ACT-281959), a Novel P2Y12 Receptor Antagonist with a Wider Therapeutic Window in the Rat Than Clopidogrel. J Med Chem. 2015 Dec 10;58(23):9133-53.

PeptideDB